Mark S. Shearman - 13 Feb 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: EVP, CHIEF SCIENTIFIC OFFICER
Issuer ticker: EDIT
Reported as of: 13 Feb 2023
Net transaction value: -$26,966
SEC form: 4
Accepted by SEC: 15 Feb 2023, 15:30:45 UTC
Prior SEC filing: 16 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Mark Shearman

Key filing fact

Mark S. Shearman filed Form 4 for Editas Medicine, Inc. (EDIT) on 15 Feb 2023.

Key facts

This page summarizes Mark S. Shearman's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Feb 2023, 15:30.

Change

Previous filing in this sequence was filed on 16 Jun 2022.
Current net transaction value: -$26,966.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value: $26,966
Shares: -2,790
Change %: -4.1%
Price: $9.67
Shares after: 65,559
Date: 13 Feb 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.